CVS Splits Itself in the Name of Strength — and the Market Shrugs
The breakup is the story
After eight quarters of beat-and-raise, CVS Health chose its strongest-looking moment to break itself in two. David Joyner opened the call with the announcement that the company intends to “separate into 2 independent publicly traded companies” — J. David Joyner CEBS, Chairman and Chief Executive Officer · 2026-11-04. The remaining CVS Health keeps Aetna, Caremark, specialty pharmacy, Oak Street and Signify; the new CVS Pharmacy takes the retail stores, mail order, MinuteClinic and Health 100. The deal is expected to be tax-free and to close in the first half of 2028. Joyner framed it as “a position of strength” — J. David Joyner CEBS, Chairman and Chief Executive Officer · 2026-11-04 — a phrase he used repeatedly — and pointed to eight quarters of execution, a repaired balance sheet and the earlier-than-planned target leverage.
The tape is telling a different story. CVS shares are down 22.7% over the last 90 trading days and sit 27.7% below the July 21 peak of $110.60. That is the tension in this report: operationally, CVS is stronger than it has been in years; strategically, it is asking investors to underwrite a complex separation, two equity stories and a 15-to-18-month execution window. A breakup can unlock value, but it also advertises that the conglomerate discount was real.
The numbers underneath the announcement
The quarter itself was solid. CVS generated more than $108 billion of revenue, $4.2 billion of adjusted operating income and $2.09 of adjusted EPS, up more than 30% year over year. Year-to-date cash flow from operations reached $15.3 billion. Management raised 2026 adjusted EPS guidance to at least $8.20, revenue to at least $420 billion, enterprise adjusted operating income to at least $17.05 billion and cash flow from operations to at least $15.5 billion. In the latest filed quarter, the recovery was already visible: operating income reached $4.7 billion, up 98% year over year, while free cash flow hit $5.5 billion, up 375%. The balance sheet has improved too, though it is still in a net debt position: effective net cash was negative $15.9 billion.
The segment detail supports the margin improvement claim. Healthcare Benefits delivered $900 million of adjusted operating income, up nearly $600 million, with a medical benefit ratio of 91.3%, about 150 basis points better. Health Services earned $2.1 billion, up nearly 3%. Pharmacy and Consumer Wellness earned more than $1.6 billion, up more than 10%, on same-store prescription volume growth of nearly 4%. That is not a broken company. It is a company whose parts are finally performing at the same time — which is exactly why the board can contemplate a split.
The trough they want you to underwrite
The harder issue is 2027. Brian Newman set a floor of at least $8.65 in adjusted EPS, about 13% growth off the adjusted 2026 baseline.
We now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline.
He also called out the shape of Health Services: at least $7 billion of adjusted operating income in 2027, a year-over-year decline in the 340B business, pressure from a less robust selling season and health plan client membership attrition, partly offset by specialty and healthcare delivery. Then the line that matters: “We are confident 2027 will reflect trough earnings for this segment, and we expect to return to growth from there.” — Brian O. Newman, Chief Financial Officer · 2026-11-04 That is a clear trough earnings story. It is also a change in tone. On the prior call, Newman gave a “a reasonable floor, Mike, for '27 for adjusted EPS should be -- could be $8.44” — Brian Newman · 2026-08-05, and Prem Shah said CVS “we did experience some pressure from 340B in the quarter and now expect that to be a headwind as we go into next year.” — Prem Shah · 2026-08-05 The new message is that the headwind is sized, ring-fenced and largely over by the end of 2027. Shah went further: “we do not expect this to be a topic we need to discuss going forward.” — Prem S. Shah, Chief Pharmacy Officer / President, Pharmacy · 2026-11-04
Investors have heard that kind of simplification before. The difference this time is structural: the split forces CVS to replace internal integration with commercial agreements. Joyner was explicit that the companies will preserve the products that made CVS and Caremark better together, but through contracts rather than an operating structure. “We need to make sure that we are aligned around where we believe that there can be value creation and ensure that there is an appropriate commercial agreement in place to support that.” — J. David Joyner CEBS, Chairman and Chief Executive Officer · 2026-11-04 That is the bet: the economics can survive the firewall, and each company can allocate capital more cleanly. If the contracts work, the sum of the parts should be worth more than the whole. If they do not, the split simply transfers integration risk to shareholders.
Why the stock is not cheering
CVS is cheap on revenue: price-to-revenue is about 0.3x, even after a 41% year-over-year re-rating in that multiple. But cheapness is not a catalyst when the company is asking for patience through a separation, a 2027 trough and a PBM selling season that has yet to prove itself. The market may also be looking past the raise to the capital deployment question: CVS will restart buybacks in the fourth quarter, but the 2027 guide assumes only offsetting dilution, not a net benefit. That is conservative, but it leaves the upside to execution rather than the balance sheet.
The stock’s 90-day drawdown is the loudest signal in this dossier. It says the market is not treating the split as a victory lap; it is treating it as a reset. The company’s job now is to prove that two focused companies can grow faster than one diversified one — and that the 2027 trough really is a trough. Until then, the phrase position of strength will read as management’s framing, not the market’s verdict.